References
- Law M, Yang S, Wang H, Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98.
- Hsu YY, Chang CN, Wie KJ, Proton magnetic resonance spectroscopic imaging of cerebral gliomas: correlation of metabolite ratios with histopathologic grading. Chang Gung Med J 2004;27:399–407.
- Chawla S, Wang S, Wolf RL, Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683–89.
- Rijpkema M, Schuuring J, van der Meulen Y, Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16:12–18.
- Chawla S, Oleaga L, Wang S, Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging 2010;20:3–8.
- Zeng QS, Li CF, Zhang K, Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84:63–9.
- Murphy PS, Viviers L, Abson C, Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781–86.
- Law M, Cha S, Knopp EA, High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222: 715–21.
- Chiang IC, Kuo YT, Lu CY, Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004;46:619–27.
- McBride DQ, Miller BL, Nikas DL, Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995;44:137–44.
- Server A, Josefsen R, Kulle B, Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiologica 2010;51:316–25.
- Bertossi M, Virgintino D, Maiorano E, Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 1997;2:41–9.
- Murphy M, Loosemore A, Clifton AG, The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg 2002;16: 329–34.
- Martinez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging 2009;53:618–30.
- Poptani H, Gupta RK, Roy R, Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593–603.
- Galanaud D, Chinot O, Metellus P, Input of magnetic resonance spectroscopy in gliomas explorations. Bull Cancer 2005;92:327–31.
- Cha S, Lupo JM, Chen MH, Differentiation of glioblastoma multiforme and single brain metastases by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007;28:1078–84.
- Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279–89.
- Kelly PJ, Daumas-Duport C, Scheithauer BW, Stereotactic histologic correlations of computed tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450–9.
- Daumas-Duport C, Monsaigneo V, Blond S, Serial stereotactic biopsies and CT scan gliomas: correlative study in 100 astrocytomas, oligo-astrocytomas and oligodendrogliomas. J Neurooncol 1987;4:317–28.
- Ricci R, Bacci A, Tugnoli V, Metabolic findings on 3T 1H-MR spectroscopy in peritumoral brain edema. Am J Neuroradiol 2007;28:1287–91.
- Cha S, Lupo JM, Chen MH, Differentiation of glioblastoma multiforme and single brain metastases by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007;28:1078–84.
- Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004;15:279–89.
- Chawla S, Zhang Y, Wang S, Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. Comput Assist Tomogr 2010;34:836–41.
- Bendini M, Marton E, Feletti A, Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients. Acta Neurochir (Wien) 2011;153:403–12.
- Bruhn H, Frahm J, Gyngell ML, Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172:541–8.
- Weber MA, Zoubaa S, Schlieter M, Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006;66:1899–906.
- Fayed N, Dávila J, Medrano J, Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Eur J Radiol 2008;67:427–33.
- Young RJ, Sills AK, Brem S, Neuroimaging of metastatic brain disease. Neurosurgery 2005;57:10–23.
- Kelly PJ, Daumas-Duport C, Kispert DB, Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865–74.
- Opstad KS, Murphy MM, Willins PR, Differentiation of metastases from high-grade gliomas using short echo time 1 H spectroscopy. J Magn Reson Imaging 2004;20: 187–92.
- Fan G, Sun B, Wu Z, In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004;59:77–85.